INDP Stock Summary and Trading Ideas (Indaptus Therapeutics | NASDAQ:INDP)

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Indaptus Therapeutics trades on the NASDAQ stock market under the symbol INDP.

As of March 5, 2025, INDP stock price climbed to $0.83 with 2,425 million shares trading.

INDP has a beta of 1.46, meaning it tends to be more sensitive to market movements. INDP has a correlation of 0.08 to the broad based SPY ETF.

INDP has a market cap of $9.97 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, INDP traded as high as $4.25 and as low as $.70.

The top ETF exchange traded funds that INDP belongs to (by Net Assets): VTI, VXF.

INDP has underperformed the market in the last year with a return of -64.8%, while the SPY ETF gained +15.3%. In the last 3 month period, INDP fell short of the market, returning -14.6%, while SPY returned -3.6%. However, in the most recent 2 weeks INDP has outperformed the stock market by returning +7.8%, while SPY returned -4.5%.

INDP support price is $.76 and resistance is $.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INDP shares will trade within this expected range on the day.